

Attorney Docket No.: 930008-2210 (BOE0006US.NP)
Inventors: Runge and Lembcke
Serial No.: 10/593,657
Filing Date: April 16, 2007
Page 2

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-36 (canceled).

Claim 37 (previously presented): A pharmaceutical formulation comprising crystalline and/or amorphous unmilled flutamide particles mixed with at least one surface-active substance, wherein the flutamide has been subjected to intensive mixing in a forced-action mixer with the at least one surface-active substance, wherein the size of 50% of the flutamide particles in the pharmaceutical formulation is greater than 26 μm .

Claim 38 (previously presented): The pharmaceutical formulation of claim 37, wherein said formulation further comprises at least one flow regulator and is in the form of a tablet.

Claim 39 (previously presented): The pharmaceutical formulation of claim 37, wherein said formulation is in the form of a filling for capsules.

Claim 40 (previously presented): The pharmaceutical formulation of claim 37, wherein said formulation is in the form of a dragée, effervescent tablet, suppository or granulate.

Attorney Docket No.: 930008-2210 (BOE0006US.NP)
Inventors: Runge and Lembcke
Serial No.: 10/593,657
Filing Date: April 16, 2007
Page 3

Claim 41 (previously presented): The pharmaceutical formulation of claim 37, wherein the flutamide has been subjected to recrystallisation.

Claims 42-45 (canceled).

Claim 46 (currently amended): The pharmaceutical formulation of claim ~~45~~37, wherein the size of 90% of the flutamide particles (X90 value) is greater than 130 μm .

Claims 47-48 (canceled).

Claim 49 (currently amended): The pharmaceutical formulation of claim ~~48~~37, wherein the flutamide particles have a specific surface area of less than $0.35 \text{ m}^2/\text{cm}^3$.

Claim 50 (previously presented): The pharmaceutical formulation of claim 37, wherein the flutamide is in the form of a free acid amide.

Claim 51 (previously presented): The pharmaceutical formulation of claim 37, wherein the at least one surface-active substance is selected from the group of an anionic compound, cationic compound and non-ionic surfactant.

Claim 52 (previously presented): The pharmaceutical formulation of claim 51 comprising sodium dodecylsulphate as surface-active substance.

Attorney Docket No.: 930008-2210 (BOE0006US.NP)
Inventors: Runge and Lembcke
Serial No.: 10/593,657
Filing Date: April 16, 2007
Page 4

Claim 53 (previously presented): The pharmaceutical formulation of claim 37 with a ratio by weight of flutamide:surface-active substance of from 5:1 to 30:1.

Claim 54 (previously presented): The pharmaceutical formulation of claim 53 with a ratio by weight of flutamide:surface-active substance of from 5:1 to 20:1.

Claim 55 (previously presented): The pharmaceutical formulation of claim 54 with a ratio by weight of flutamide:surface-active substance of from 10:1 to 15:1.

Claim 56 (previously presented): The pharmaceutical formulation of claim 37 in the form of an unshaped mixture or in the form of an article that has been subjected to shaping.

Claim 57 (previously presented): The pharmaceutical formulation of claim 56 with a content of from 50 to 2000 mg of flutamide.

Claim 58 (previously presented): The pharmaceutical formulation of claim 57 with a content of from 50 to 500 mg of flutamide.

Claim 59 (previously presented): The pharmaceutical formulation of claim 58 with a content of from 100 to 200 mg of flutamide.

Attorney Docket No.: 930008-2210 (BOE0006US.NP)
Inventors: Runge and Lembcke
Serial No.: 10/593,657
Filing Date: April 16, 2007
Page 5

Claim 60 (previously presented): The pharmaceutical formulation of claim 37, further comprising at least one excipient selected from the group formed by inorganic fillers, organic fillers, binders, glidants, lubricants, flow regulators and disintegrants.

Claim 61 (previously presented): The pharmaceutical formulation of claim 37, wherein the formulation is mixed in a forced-action mixer for 1 to 180 minutes.

Claim 62 (previously presented): The pharmaceutical formulation of claim 61, wherein the formulation is mixed in a forced-action mixer for 3 to 60 minutes.